Synairgen plc Notice of Interim Results (2364J)
September 08 2016 - 1:01AM
UK Regulatory
TIDMSNG
RNS Number : 2364J
Synairgen plc
08 September 2016
PRESS RELEASE
8 September 2016
SYNAIRGEN PLC
("Synairgen" or "the Company")
Notice of Interim Results
Southampton, UK, 8 September 2016: Synairgen plc (LSE: SNG), the
respiratory drug discovery and development company, will issue its
interim results for the six-month period ended 30 June 2016 on 22
September 2016.
ENDS
For further information, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
finnCap
Geoff Nash, James Thompson (Corporate Finance)
Stephen Norcross, Simon Johnson (Corporate Broking)
Tel: + 44 (0) 20 7220 0500
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Sue Stuart / Laura Thornton
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5701
Notes for Editors
About Synairgen
Synairgen is a respiratory drug discovery and development
company founded by University of Southampton Professors Stephen
Holgate, Donna Davies and Ratko Djukanovic. The business, focused
primarily on asthma and COPD, uses its differentiating human
biology BioBank platform and world-renowned international academic
KOL network to discover and develop novel therapies for respiratory
disease. Leveraging its scientific and clinical facilities at
Southampton General Hospital, the Company uses in vitro and ex vivo
models to progress opportunities into clinical development. The
BioBank of human samples is used in these models to increase
confidence in the likelihood of successful drug development. Core
to Synairgen's business strategy is the realisation of value via
licensing transactions. This approach has been validated by the
licensing agreement formed with AstraZeneca in June 2014 for
Synairgen's SNG001 (AZD9412) programme in asthma/COPD. In August
2015 the Company entered into a collaboration with Pharmaxis to
develop an oral LOXL2 inhibitor to reduce fibrosis in patients with
idiopathic pulmonary fibrosis (IPF). Synairgen is quoted on AIM
(LSE: SNG). For more information about Synairgen, please see
www.synairgen.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORUGURGBUPQGAM
(END) Dow Jones Newswires
September 08, 2016 02:01 ET (06:01 GMT)
Synairgen (LSE:SNG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Synairgen (LSE:SNG)
Historical Stock Chart
From Apr 2023 to Apr 2024